Skip to content
MarketScale
‹ Back to IndustriesSciences

A Propensity to Talk Density: Exploration Challenges and Opportunities in Malaysia

Roy Kittrell, Regional Geologist (Asia Pacific) at Bell Geospace, is a veteran in the oil & gas space. After fifteen years in the industry, Kittrell said he’s worked on everything from core analysis centimeter-scale geology to field scales with geological modeling. So, how did this dual national American/British Geologist find himself working for Bell Geospace…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By MarketScale · Basement MappingExplorationFull Tensor Gravity GradiometryLineaments Analysis
Share

Key takeaways

01

Roy Kittrell, Regional Geologist (Asia Pacific) at Bell Geospace, is a veteran in the oil & gas space.

02

After fifteen years in the industry, Kittrell said he’s worked on everything from core analysis centimeter-scale geology to field scales with geological modeling.

03

So, how did this dual national American/British Geologist find himself working for Bell Geospace…

Roy Kittrell, Regional Geologist (Asia Pacific) at Bell Geospace, is a veteran in the oil & gas space. After fifteen years in the industry, Kittrell said he’s worked on everything from core analysis centimeter-scale geology to field scales with geological modeling. So, how did this dual national American/British Geologist find himself working for Bell Geospace in Kuala Lumpur, Malaysia? He sat down with Tyler Kern to fill him in on his journey.

For the past five years, Kittrell’s base has been Malaysia, a country he finds rich in national heritage with one of the highest biodiversities of any country. It’s a perfect place for exploration in and outside his duties at Bell Geospace.

The current outlook for geological exploration in Malaysia points to a strong year with many opportunities. Kittrell said Bell Geospace was well-positioned to offer data on a lot of these onshore and offshore areas. “We have a new system where we’re going to be offering data packages at a reduced rate, and they are available for rent. So, you can rent the data for a full year, and you only pay for the part that’s over your block if you win it.” And Bell provides many different data packages for interested parties.

The secret behind Bell Geospace’s stunningly detailed maps is their utilization of FTG, full tensor gravity gradiometry. “It maps out density contrasts in the subsurface,” Kittrell said. “So, using that, we can generate some really amazing maps of the regional geology at a huge scale, and basement mapping is one of the things that FTG is extremely good at.”

While FTG can’t pinpoint where sought-after Hydrocarbon reserves are, it does provide clues and ideas of what the regional geology and the structure maps are doing. “We have some case studies to show where it correlates to a lot of the known hydrocarbon accumulations.”

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

M
MarketScale

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512